Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
12
2021
accepted:
11
03
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
To report on the short-term outcome of intravitreal brolucizumab in patients with neovascular age-related macular degeneration (nAMD). This is a prospective, interventional, monocentric study on 10 eyes of 10 patients with a treatment-naïve neovascular AMD. Patients were treated according to the HAWK and HARRIER trials. After loading with 3 monthly injections, eyes received an injection 12 weeks after the upload (q12w) or were adjusted to an 8 week interval (q8w), if disease activity was present 8 weeks after the upload. Main outcome measures were the change in central retinal thickness (CRT) assessed by spectral domain optical coherence tomography (SD-OCT), the change in macular neovascularization (MNV) size on optical coherence tomography angiography (OCTA), and the change in best corrected visual acuity (BCVA) 8 and 12 weeks after the upload. We further assessed clinical parameters that predict the treatment response at baseline based on the need of q8w or q12w injections after the upload. CRT decreased significantly from 461.7 ± 82.9 Brolucizumab appears to be a valuable tool for the management of patients with nAMD. Furthermore, MNV size at baseline might serve as an early predictor of treatment response.
Sections du résumé
Background
UNASSIGNED
To report on the short-term outcome of intravitreal brolucizumab in patients with neovascular age-related macular degeneration (nAMD).
Methods
UNASSIGNED
This is a prospective, interventional, monocentric study on 10 eyes of 10 patients with a treatment-naïve neovascular AMD. Patients were treated according to the HAWK and HARRIER trials. After loading with 3 monthly injections, eyes received an injection 12 weeks after the upload (q12w) or were adjusted to an 8 week interval (q8w), if disease activity was present 8 weeks after the upload. Main outcome measures were the change in central retinal thickness (CRT) assessed by spectral domain optical coherence tomography (SD-OCT), the change in macular neovascularization (MNV) size on optical coherence tomography angiography (OCTA), and the change in best corrected visual acuity (BCVA) 8 and 12 weeks after the upload. We further assessed clinical parameters that predict the treatment response at baseline based on the need of q8w or q12w injections after the upload.
Results
UNASSIGNED
CRT decreased significantly from 461.7 ± 82.9
Conclusions
UNASSIGNED
Brolucizumab appears to be a valuable tool for the management of patients with nAMD. Furthermore, MNV size at baseline might serve as an early predictor of treatment response.
Identifiants
pubmed: 35369000
doi: 10.1155/2022/2659714
pmc: PMC8975682
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2659714Informations de copyright
Copyright © 2022 Anne Rübsam et al.
Déclaration de conflit d'intérêts
AR received speaking honoria from Bayer Healthcare and Novartis and served as consultant for Novartis. AR receives research support from Deutsche Forschungsgemeinschaft (DFG) (RU 2020/3-1) and is a participant in the BIH-Charité Clinician Scientist Program funded by Charité–Universitätsmedizin Berlin and the Berlin Institute of Health. SR received speaking honoraria from Bayer Healthcare and Novartis. DP reports no conflicting interests. OZ has served as consultant for Allergan, Bayer, Novartis, Omeicos, Oxular, Roche, SamChungDang Pharma, and Boehringer-Ingelheim. OZ received speaker honoraria from Allergan, Bayer, Novartis, Roche, and Boehringer-Ingelheim. AJ has served as consultant for Novartis, Bayer, Roche, and Boehringer-Ingelheim. AJ received speaker honoraria from Novartis, Bayer, Roche, and Boehringer-Ingelheim and served as Advisory Board Member and expert for Novartis, Roche, Bayer, and Boerhinger-Ingelheim.
Références
Am J Ophthalmol Case Rep. 2020 Apr 02;18:100687
pubmed: 32280811
J Manag Care Spec Pharm. 2018 Feb;24(2-a Suppl):S3-S15
pubmed: 29383980
Int J Environ Res Public Health. 2021 Aug 10;18(16):
pubmed: 34444199
Am J Ophthalmol. 2007 Jul;144(1):15-22
pubmed: 17509509
Clin Ophthalmol. 2021 Sep 07;15:3787-3795
pubmed: 34522081
Ophthalmology. 2016 May;123(5):1080-9
pubmed: 26906165
Retina. 1990;10(1):1-8
pubmed: 1693009
Br J Ophthalmol. 2019 Jan;103(1):67-71
pubmed: 29567794
Arch Ophthalmol. 1997 Apr;115(4):478-85
pubmed: 9109756
J Comp Eff Res. 2018 Nov;7(11):1125-1132
pubmed: 30238792
Eye (Lond). 2021 Apr;35(4):1045-1047
pubmed: 32709960
Am J Ophthalmol. 2012 Feb;153(2):209-213.e2
pubmed: 22264944
J Clin Med. 2021 Sep 15;10(18):
pubmed: 34575264
Eye (Lond). 2020 Oct;34(10):1726-1728
pubmed: 32251366
Ophthalmol Retina. 2019 Aug;3(8):629-636
pubmed: 31068262
J Vitreoretin Dis. 2020 Jul;4(4):269-279
pubmed: 32789284
Biomedicines. 2021 Jun 10;9(6):
pubmed: 34200829
Br J Ophthalmol. 2021 Apr 12;:
pubmed: 33846161
Graefes Arch Clin Exp Ophthalmol. 2000 Sep;238(9):752-9
pubmed: 11045343
Ophthalmology. 2021 Jan;128(1):89-99
pubmed: 32574761
Ophthalmology. 2020 Jan;127(1):72-84
pubmed: 30986442
Clin Exp Ophthalmol. 2018 Mar;46(2):189-200
pubmed: 29178419
Br J Ophthalmol. 2000 May;84(5):479-84
pubmed: 10781511
Am J Ophthalmol Case Rep. 2020 Mar 31;18:100680
pubmed: 32258827
Ophthalmologe. 2021 Mar;118(3):248-256
pubmed: 33555415
JAMA Ophthalmol. 2021 Apr 1;139(4):441-448
pubmed: 33630045
Br J Ophthalmol. 2016 Jul;100(7):914-917
pubmed: 26516125
J Clin Med. 2021 Jun 23;10(13):
pubmed: 34201729
Ophthalmol Retina. 2018 Sep;2(9):931-941
pubmed: 30238069
Sci Rep. 2021 Mar 24;11(1):6759
pubmed: 33762600
Eye (Lond). 2021 May;35(5):1292-1294
pubmed: 33082532